ArriVent’s firmonertinib failed against chemo on PFS in NSCLC with exon 20 insertion mutations, but the firm also has the EGFR inhibitor in Phase III for the larger PACC mutation subpopulation.
ArriVent’s firmonertinib failed against chemo on PFS in NSCLC with exon 20 insertion mutations, but the firm also has the EGFR inhibitor in Phase III for the larger PACC mutation subpopulation.